Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …

Summary Background SIM0417 (SSD8432) is an orally administered coronavirus main
proteinase (3CL pro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

Background: Limited treatment options exist for patients with mild-to-moderate coronavirus
disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a …

The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable
clinical severity and ability to escape preexisting immunity emphasizes the continued need …

Importance Some patients treated with nirmatrelvir-ritonavir have experienced rebound of
COVID-19 infections and symptoms; however, data are scarce on whether viral rebound …

Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged)
were approved by the Chinese National Medical Products Administration for the treatment of …

Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …

Importance Postmarket analysis of individuals who receive nirmatrelvir and ritonavir
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …

The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …